Patent Expiry
TGTX: ORBACTIV: recorded patent 9649352 expiry
July 16, 2035 · ORITAVANCIN DIPHOSPHATE. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 16, 2035
- Company
- TG THERAPEUTICS, INC. (TGTX)
- Drug
- ORITAVANCIN DIPHOSPHATE
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Patent Expiry
ORBACTIV: recorded patent 9649352 expiry
Orange Book application NDA206334, product 001, listed patent 9649352 expiry. Overall loss of exclusivity and current company rights: unknown.FDA source
- Company
- TG THERAPEUTICS, INC. (TGTX)
- Drug
- ORITAVANCIN DIPHOSPHATE